ORTHO D- folic acid and vitamin d3 capsule 
Solubiomix

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

----------

Ortho D

DESCRIPTION:

Ortho D Capsules is an orally administered prescription folate product for the dietary management of patients with unique nutritional needs requiring increased folate levels and Vitamin D supplementation due to Vitamin D deficiency and other nutritional supplementation.
Ortho D should be administered under the supervision of a licensed medical practitioner.
Vitamin D3 (cholecalciferol) is a white, crystalline powder, very soluble in water, with the following structural formula:]:

image description

Each capsule contains:
          Folic Acid ............................................................................1 mg
          Vitamin D3 (Cholecalciferol) .............................................3775 IU


Each capsule contains the following inactive ingredients: Gelatin, cellulose, magnesium stearate, silica.

INDICATIONS AND USAGE:

Ortho D is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels, Vitamin D deficiency or are in need of Vitamin D supplementation and other nutritional supplementation.


Ortho D can be taken by women of childbearing age, pregnant women, and lactating and nonlactating mothers.

CLINICAL PHARMACOLOGY:

The in vivo synthesis of the major biologically active metabolites of vitamin D occurs in two steps. The first hydroxylation of ergocalciferol takes place in the liver (to 25-hydroxyvitamin D) and the second in the kidneys (to 1,25-dihydroxyvitamin D). Vitamin D metabolites promote the active absorption of calcium and phosphorus by the small intestine, thus elevating serum calcium and phosphate levels sufficiently to permit bone mineralization. Vitamin D metabolites also mobilize calcium and phosphate from bone and probably increase the reabsorption of calcium and perhaps also of phosphate by the renal tubules.


There is a time lag of 10 to 24 hours between the administration of vitamin D and the initiation of its action in the body due to the necessity of synthesis of the active metabolites in the liver and kidneys. Parathyroid hormone is responsible for the regulation of this metabolism in the kidneys.

CONTRAINDCATIONS:

This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. Ortho D is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.

WARNINGS AND PRECAUTIONS:

KEEP OUT OF THE REACH OF CHILDREN.

Tell your doctor if you have: kidney problems, thyroid disease. This medication should be used as directed during pregnancy or while breast-feeding. Consult your doctor about the risks and benefits.


Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient. Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.

ADVERSE REACTIONS:

Allergic sensitization has been reported following both oral and parenteral administration of folic acid.
You should call your doctor for medical advice about serious adverse events. To report adverse side effects or to obtain product information, contact Solubiomix, LLC, at 1-844-551-9911.

DOSAGE AND ADMINISTRATION:

Take one capsule daily or as directed by a healthcare practitioner.

HOW SUPPLIED:

Ortho D capsules are supplied as clear capsules printed with “301” dispensed in child-resistant bottles of 30ct (69499-301-30*).


* This product is a prescription-folate with or without other dietary ingredients that – due to increased folate levels (AUG 2 1973 FR 20750), requires an Rx on the label because of increased risk associated with masking of B12 deficiency (pernicious anemia). Based on our assessment of the risk of obscuring pernicious anemia, this product requires licensed medical supervision, an Rx status, and a National Drug Code (NDC) – or similarly-formatted product code, as required by pedigree reporting requirements and supply-chain control as well as – in some cases, for insurance-reimbursement applications.
All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision. There are no implied or explicit claims on therapeutic equivalence.

STORAGE:

KEEP OUT OF THE REACH OF CHILDREN.

Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature.]
Protect from heat, light and moisture.

Tamper Evident: Do not use if seal is broken or missing

PACKAGE LABEL DISPLAY PANEL:

image description

ORTHO D 
folic acid and vitamin d3 capsule
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:69499-301
Route of AdministrationORAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
FOLIC ACID (UNII: 935E97BOY8) (FOLIC ACID - UNII:935E97BOY8) FOLIC ACID1 mg  in 1 mg
VITAMIN D (UNII: 9VU1KI44GP) (CHOLECALCIFEROL - UNII:1C6V77QF41) VITAMIN D.094 mg  in 1 mg
Inactive Ingredients
Ingredient NameStrength
GELATIN (UNII: 2G86QN327L)  
CELLULOSE ACETATE (UNII: 3J2P07GVB6)  
MAGNESIUM STEARATE (UNII: 70097M6I30)  
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
Product Characteristics
Colorwhite (Clear capsule) Scoreno score
ShapecapsuleSize18mm
FlavorImprint Code 301
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:69499-301-3030 mg in 1 BOTTLE; Type 0: Not a Combination Product08/08/201510/02/2018
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
unapproved drug other08/08/201510/02/2018
Labeler - Solubiomix (079640556)
Establishment
NameAddressID/FEIBusiness Operations
Solubiomix079640556label(69499-301)

Revised: 10/2018
 
Solubiomix